Document is current
Any future updates will be listed below
-
Authors
Andreasen, Camilla
Dahl, Cecilie
Frihagen, Frede
Borgen, Tove T.
Basso, Trude
Gjertsen, Jan-Erik
Figved, Wender
Wisløff, Torbjørn
Hagen, Gunhild
Apalset, Ellen M.
Stutzer, Jens M.
Lund, Ida
Hansen, Ann K.
Nissen, Frida I.
Joakimsen, Ragnar M.
Syversen, Unni
Eriksen, Erik F.
Nordsletten, Lars
Omsland, Tone K.
Bjørnerem, Åshild
Solberg, Lene Bergendal https://orcid.org/0000-0002-8705-5033
-
Funding
Funding for this research was provided by:
Helse Nord RHF (14083)
Helse Sør-Øst RHF (2017032)
Norges Forskningsråd (243852)
St. Olavs Hospital Universitetssykehuset i Trondheim (46055600-51)
Vestre Viken Helseforetak (19003007)
University of Oslo
- License Information
-
More Information
Article History
Received: 18 August 2024
Accepted: 23 December 2024
First Online: 14 January 2025
Declarations
:
: All procedures performed in the study were in accordance with the 1964 Helsinki Declaration and its later amendments. The study was approved by the Regional Committee of Medical and Health Research Ethics (REK 2015/334). The merging of data using the personal identification number and exemption from obtaining consent for the collection of data was approved by the Regional Committee of Medical and Health Research Ethics (REK 2015/334). A Data Protection Impact Assessment (DPIA) in agreement with the General Data Protection Regulation was performed by The University of Oslo. The study was approved by the Patient Data Protection Officer (PVO) at each of the hospitals and the PVO provided exemption from obtaining consent from the participants and authorized a secure research server for storage of the audit data.
: CA, CD, TB, TW, GH, JMS, IL, AKH, FIN, LN, TKO, and ÅB no support from any organization for the submitted work; FF reports lecturing fees from UCB and Amgen; TTB reports speaker fees from UCB, Amgen, Roche Diagnostics, and Pharma Prim and participation in an advisory board for UCB. Further, FF is president of the Fragility Fracture Network which is sponsored by Amgen, UCB, and Danone; JEG reports lecture fees from Ortomedic Norway, Smith and Nephew, Heraeus Medical, and LINK Norway; WF reports lecture fees from Ortomedic Norway and Zimmer Biomet Norway; EMA reports participation in the advisory board for UCB and Amgen; RMJ reports consulting fees from Norwegian Directorate of Health, Norwegian Diabetes Association, and Northern Norway Regional Health Authority and lecture fees from Novo Nordisk, Eli-Lilly, Astra-Zeneca, and Sanofi; US reports speaker and consulting fees from Amgen, UCB, and Novartis; EFE reports consultant fees from Novartis, UCB, Amgen, Takeda, and Pharma Medico and research support from Takeda and Amgen. Further, EFE has worked as a medical consultant for the Norwegian Osteoporosis Society; LBS reports speaker fees from Eli Lilly, Amgen, and UCB. Further, LBS is the president of Fragility Fracture Network Norway.
